Towards a Virtual Trials strategy with an integrative approach, dealing with peritoneal recurrences.
I have a serious interest in the subject of peritoneal and mesenteric recurrence where this is a potential future, hopefully never, or much distant, to us. Nevertheless, I have addressed a number of possible pathways forward. Should this eventuality rear its head at us, as
previous surgical statistics (bottom, the "incomplete cytoreduction" curve, from Harmon and Sugarbaker, 2005) might suggest, I plan to have more Japanese surgical-chemo procedures implemented. Some Japanese papers that I saw, refer to or used simple interperitoneal injection of mitomycin C (MMC), rather than just intravenuos MMC. This is less aggressive than HIPEC but less strenuous too, with much less table time. Perhaps others can see more pre-surgical, simple IP-MMC possibilities.
We would also likely switch to a TS-1 protocol (not available locally here, yet, either) similar to what we do now, directly switching out the current
metronomic UFT treatment, locally available, for TS-1.
TS-1
(aka S-1), is shown to successfully replace FOLFOX/FOLFIRI as a low toxicity salvage therapy for colorectal cancer. TS-1 from Japan has similar costs to Xeloda but may functionally replace XELOX, with the extra oxaliplatin.
TS-1 was first extensively documented, approved
and recognized in Western textbooks, for peritoneal mets from far more aggressive
gastric cancers, as well as being approved in Japan for colon cancer. Also,
S-1 showed a surprisingly long-term survival with minimum toxicity in patients with peritoneal metastasis of gastric cancer. I know, "not quite the same," but TS-1 is showing across the board results as well as having firm physiological reasons to exceed previous generation 5FU products without the DPD inhibition.
We, for ourselves, would notably, presumptively, add the non/less-toxic extras like cimetidine, nutrients, and IV C+K3 to the treatment cocktail because it has worked for our single case, with a very high quality of life, and there is no sign of the "ski slope", linked and mentioned above. I cannot emphasize the quality of life with not one "chemo sick day". We will find capable help if and when necessary on any future surgery.
Perhaps there are some doctors that can find merit, appeal to the insurance pocketbook, and see daylight from the published Japanese experience, oupled with a more integrative approach.
--------------------------------------------------------------------------------------------------
Spouse dx'd March with obstructive colon cancer, stage III/IV, possible lung mets <1 cm.
Start cimetidine 1600 mg/d, bid, with modified citrus pectin, after scope+biopsy.
1 month of alt chemo, nutritional fortification before surgery (initially a marginal surgical candidate, anemic, KP score 60-70%).
Highly experienced CRC surgeon laid in multiple metal clips for radiation on non-resectable invaded area. However, pathology showed most invasive material outside colon [peritoneum] necrosed before surgery, obstructed channel opened slightly, 2 lymph nodes remained positive.
April, post op: begin IV vitamin C daily; later stepwise K3 [declined Folfox, Xelox+Av+Erb]
May: cont'd LEF + orthomolecular style nutrition every day; IV vitamin C + K3, every other day
June: begin Metronomic UFT at lowest dose, an oral chemo with tegafur; continue cimetidine, 800mg+high dose nutrients.
July: increase K3, IV vitamin C 3x week . . . . . . . . . . . 4wks pre-op: BG 130s; cholesterol: 260s, TG 200+;
Pre-op CEA: 20+, Sept. 2+; CA19-9 down 40% and stable. 1 mo post-op: BG 100s; TC 200s, TG <100, w/o meds.